Sector News

Chiltern PCR buy cements Asia-Pacific offering

September 30, 2014
Life sciences
Chiltern has made its second significant acquisition this year snapping up fellow contract research organisation Pacific Clinical Research in a move designed to secure a stronger foothold in the Asia-Pacific region.
 
The London, UK and Wilmington, NC-based group says the addition of PCR will allow it to offer integrated services throughout the Asia-Pacific (APAC) region and strengthens in particular its offering within oncology and anti-infective areas.
 
Chiltern has been considering a means of growing capabilities in APAC for some time, because there is great interest across the industry to place more clinical trials in the region, a company spokesman told PharmaTimes.
 
“We are seeing APAC regularly in RFIs [request for information] and RFPs [request for proposal] from current and prospective customers, so this puts us in a more competitive position as a truly global service provider”, he explained. 
 
Terms of the acquisition, which follows Chiltern’s summer purchase of specialist oncology and resourcing CRO Ockham, are being kept under wraps.
 
The firm now has over 2,200 staff working across 45 countries and while no other strategic changes are immediately expected, “we are always looking for ways to improve our business and will consider other opportunities that align with the needs of our customers,” the spokesman said.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach